Evidence map›Paper›PMID 40504081›Full record

Trial reportMovement disorders clinical practice2025

Changes in Gait Speed Vary Widely after the Use of Antiparkinson Medication in Persons with Parkinson's Disease.

Anson B Rosenfeldt, Cielita Lopez-Lennon, Erin Suttman, Amy Elizabeth Jansen, Eric Zimmerman, Courtney Miller, Rachel Lovati, Hubert H Fernandez, Peter B Imrey, Leland E Dibble and 1 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Movement disorders clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anson B RosenfeldtDepartment of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0001-5468-8208
Cielita Lopez-LennonDepartment of Physical Therapy and Athletic Training, University of Utah, Salt Lake City, Utah, USA.ORCID https://orcid.org/0000-0001-7438-6733
Erin SuttmanDepartment of Physical Therapy and Athletic Training, University of Utah, Salt Lake City, Utah, USA.
Amy Elizabeth JansenDepartment of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0003-3665-0374
Eric ZimmermanCenter for Neurological Restoration, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Courtney MillerDepartment of Rehabilitation Services, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Rachel LovatiDepartment of Rehabilitation Services, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Hubert H FernandezCenter for Neurological Restoration, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Peter B ImreyDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Leland E DibbleDepartment of Physical Therapy and Athletic Training, University of Utah, Salt Lake City, Utah, USA.
Jay L AlbertsDepartment of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Funding

The Cyclical Lower-extremity Exercise for Parkinson's TrialR01NS073717 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI ALBERTS, JAY L. · 2011 to 2023
$4.8M
NIH HHS 2R01NS073717NINDS NIH HHS R01 NS073717
6 · The paper itself

Abstract

backgroundAntiparkinson medications are effective in improving Parkinson's disease (PD) motor symptoms such as bradykinesia, tremor, and rigidity. The impact of antiparkinson medication on gait speed is less clear.

objectivesThe primary aim was to determine the effects of antiparkinson medication on gait speed in PD. The secondary aim was to identify characteristics associated with the magnitude of response.

methodsTwo hundred fifty individuals with PD completed the Six-Minute Walk Test on and off medication, on separate days, in a randomized order. A paired t-test and linear regression were used to assess on- to off-medication gait speed differences and their relationships with potential correlates. Using previously established values, changes in gait speed were characterized as small (0.06-0.13 m/s), moderate (0.14-0.21 m/s), and large (>0.22 m/s). Corresponding summary characteristics were provided for each classification.

resultsMean (standard deviation) gait speed significantly increased from 1.33 (0.31) to 1.40 (0.28) m/s from off to on medication. Longer disease duration, greater clinical ratings of gait and postural instability, slower functional mobility, and higher levodopa equivalent daily dose were associated with larger increases in gait speed. In sum, 131 (52%) participants experienced no improvement or an improvement that did not meet the threshold for small responder. Of the 119 (48%) participants identified as responders, 60 were classified as small, 28 moderate, and 31 large responders.

conclusionsOverall, gait speed improved with antiparkinson medication; however, individual responses varied. Gait dysfunction in PD may be caused by impairment of multiple neural circuits, some of which are less responsive to antiparkinson medication.

Indexed as

Antiparkinson AgentsGait Disorders, NeurologicParkinson DiseaseWalking SpeedAgedFemaleHumansLevodopaMaleMiddle AgedAntiparkinson AgentsLevodopaantiparkinson medicationdopaminegait speedParkinson's diseaseSix‐Minute Walk Test

Identifiers

PMID40504081
PMCPMC12715355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.